Holen Sie sich die Stockscreener-App
0.00
100.00%
-0.0941
Handel nachbörslich:
.09
0.09
+
Schlusskurs vom Vortag:
$0.0941
Offen:
$0
24-Stunden-Volumen:
0
Relative Volume:
0.00
Marktkapitalisierung:
$5.67M
Einnahmen:
$7.10M
Nettoeinkommen (Verlust:
$-31.59M
KGV:
0.00
EPS:
-2.61
Netto-Cashflow:
$-26.75M
1W Leistung:
-100.00%
1M Leistung:
-100.00%
6M Leistung:
-100.00%
1J Leistung:
-100.00%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$0.00
$0.00
52-Wochen-Spanne:
$0.00
$1.72
Palatin Technologies Inc. Stock (PTN) Company Profile
Firmenname
Palatin Technologies Inc.
Sektor
Branche
Telefon
609-495-2200
Adresse
Cedar Brook Corporate Center, 4B Cedar Brook Drive, Cranbury, NJ
Vergleichen Sie PTN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PTN
Palatin Technologies Inc.
|
0.00 | 5.67M | 7.10M | -31.59M | -26.75M | -2.61 |
|
VRTX
Vertex Pharmaceuticals Inc
|
389.08 | 99.27B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
586.96 | 62.28B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.18 | 59.14B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
707.96 | 43.34B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
300.14 | 36.72B | 3.81B | -644.79M | -669.77M | -6.24 |
Palatin Technologies Inc. Stock (PTN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2015-06-05 | Bestätigt | Canaccord Genuity | Buy |
| 2015-01-12 | Bestätigt | ROTH Capital | Buy |
| 2012-05-23 | Eingeleitet | Noble Financial | Buy |
| 2007-01-23 | Eingeleitet | Next Generation | Buy |
Palatin Technologies Inc. Aktie (PTN) Neueste Nachrichten
Palatin Technologies Trades At A Discount As Risks Stack Up - Finimize
Boehringer Expands Eyecare Horizons With Palatin Collaboration - insights.citeline.com
Boehringer Ingelheim, Palatin Technologies to develop melanocortin receptor targeted treatment for... - Medical Dialogues
Palatin Technologies, Inc. (AMEX:PTN) Q3 2025 Earnings Call Transcript - MSN
Boehringer and Palatin team up on retinal diseases research - The Pharma Letter
Boehringer Ingelheim and Palatin Technologies to develop potential first-in-class melanocortin receptor targeted treatment for patients with retinal diseases - The Manila Times
Boehringer Ingelheim and Palatin Technologies to develop - GlobeNewswire
Boehringer Ingelheim Limited - Via Ritzau
Boehringer Ingelheim and Palatin Technologies, Inc. to Develop Potential First-In-Class Melanocortin Receptor Targeted Treatment for Patients with Retinal Diseases - MarketScreener
Palatin Technologies (PTNT) Stock Price, News & Analysis - MarketBeat
Palantin Technologies to enact 1-for-50 reverse stock split - MSN
Palantin Technologies Implements Reverse Stock Split to Meet NYSE Listing Requirements - AInvest
Palatin Technologies announces 1-for-50 reverse stock split - Investing.com India
Palatin Announces 1-for-50 Reverse Stock Split - The Malaysian Reserve
Palatin Technologies announces 1-for-50 reverse stock split By Investing.com - Investing.com Nigeria
Palatin Announces 1-For-50 Reverse Stock Split - Barchart.com
Palatin Technologies Stockholders Approve Key Governance Changes - TipRanks
Palatin Technologies shareholders approve reverse stock split and board elections - Investing.com
Palatin Reports Fiscal Year 2025 Third Quarter Results and Business Update - ADVFN Brasil
Why This French Biotech Stock Just Soared 586% In One Day - Barchart.com
Palatin Technologies reports efficacy of PL-7737 in obesity model - BioWorld MedTech
Palatin Announces Positive Preclinical Efficacy Data for Oral MC4R Agonist PL7737 in Animal Model of Obesity - The Malaysian Reserve
Palatin announces positive preclinical efficacy data for oral MC4R agonist PL7737 in animal model of obesity - MarketScreener
Breakthrough Oral Weight Loss Drug Achieves 15% Reduction When Combined with Tirzepatide in Just 4 Days - Stock Titan
Palatin Technologies receives NYSE American delisting notice, appeals decision By Investing.com - Investing.com Nigeria
Palatin Technologies receives NYSE American delisting notice, appeals decision - Investing.com Australia
Palatin Technologies Announces Closing of Reduced Public Offering (PR Newswire) - Aktiellt
Palatin Technologies Executives Make Massive Stock Purchases! - TipRanks
Palatin Technologies Raises $340K in Private Placement - TipRanks
Palatin Technologies, Inc. announced that it expects to receive $0.34 million in funding - MarketScreener
Palatin Technologies (PALI) Teams Up with Key Managers for Inves - GuruFocus
Palatin Technologies (PALI) Teams Up with Key Managers for Investment Strategy | PALI Stock News - GuruFocus
Palatin Technologies (NYSE:PTN) Coverage Initiated by Analysts at StockNews.com - Defense World
Moderate Dry Eye Market Growth to Accelerate in Forecast Period (2023-2032), DelveInsight Analyzes | mc2 therapeutics, Palatin Technologies, Novaliq - The Globe and Mail
Palatin Technologies Inc (PTNT) Q3 2025 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance
Palatin Technologies Inc (PTNT) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - GuruFocus
Earnings call transcript: Palatin’s Q3 FY2025 shows narrower loss By Investing.com - Investing.com Nigeria
Earnings call transcript: Palatin’s Q3 FY2025 shows narrower loss - Investing.com Australia
Palatin Technologies Q1 Net Loss Narrows On Lower Expenses - Nasdaq
Palatin Technologies (PTN) to Release Quarterly Earnings on Wednesday - Defense World
Palatin Technologies director Robert DeVeer buys $10,180 in stock By Investing.com - Investing.com UK
Palatin Technologies director Robert DeVeer buys $10,180 in stock - Investing.com
Palatin reveals potential diabetic retinopathy treatments - Investing.com
Finanzdaten der Palatin Technologies Inc.-Aktie (PTN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.98%
8.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):